$280 Million

Seres Therapeutics, Inc.

Follow-on Offering

Lead Left Bookrunner, August 2020

Seres Therapeutics, Inc.

Seres Therapeutics, Inc. (“Seres” or the “Company”) is a microbiome therapeutics platform company developing a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore heath by repairing the function of a dysbiotic microbiome to a non-disease state. The Company’s lead product candidate, SER-109, is designed to prevent further recurrences of Clostridioides difficile infection (formerly Clostridium difficile infection) (“CDI”), a debilitating infection of the colon, in patients who have received antibiotic therapy for recurrent CDI by treating the dysbiosis of the colonic microbiome. The Company is also developing SER-287 and SER-301 to treat ulcerative colitis (“UC”).